In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Philips buys into economy heart X-ray market with Alpha X-Ray purchase

This article was originally published in Clinica

Executive Summary

Medtech giant Philips is set to purchase Indian cardiovascular firm Alpha X-Ray Technologies for an undisclosed fee. The Dutch group will benefit from Alpha’s presence in the budget segment of the market for cardiovascular X-ray systems. This segment is said to be expanding the quickest, with annual growth rates expected to reach 10-15% in the coming years, said Philips. This deal, anticipated to close in the fourth quarter of 2008, is part of the company’s drive to invest in emerging markets – earlier this year the Amsterdam, the Netherlands-based firm bought Brazilian healthcare manufacturer Dixtal Biomedica e Tecnologia (see Clinica No 1307, p 17) and Chinese patient monitoring company Shenzhen Goldway Industrial (see Clinica No 1302, p 15).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT041656

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel